Reading the BPTAP mandate: what the panel actually assesses

The Benefits Package and Tariffs Advisory Panel is new enough that most of what is said about it is inference. The published record is narrower than the speculation, and worth reading precisely.

The verified record

The Ministry of Health established the panel through Gazette Notice No. 5044 of 23 April 2025. It was inaugurated at Afya House on 26 May 2025, chaired by Prof. Walter Jaoko, with its secretariat at the Centre for Epidemiological Modelling and Analysis at the University of Nairobi.

Its stated mandate is to review and recommend the essential health benefits package, advise on tariffs, identify priority interventions currently missing from the package, and monitor implementation by the Social Health Authority. Its method is health technology assessment. It advises the Ministry of Health and SHA.

What the mandate does not say

The public record does not describe an open applicant pathway. There is no published route by which a manufacturer files a dossier and receives a determination, in the way a national regulator or an established HTA agency operates.

This distinction matters commercially, and it is worth being blunt about it. A consultancy promising to file with the panel and secure an outcome is describing a process that has not been published. What can be done is narrower and more useful: build the evidence base an assessment requires, and engage the Ministry, SHA and the secretariat in a structured way, sequenced so that evidence arrives when it can be considered.

Why the distinction is an advantage

An assessment panel working through HTA needs the same evidence regardless of the procedural route by which it arrives. Clinical effectiveness against a local comparator, an incremental cost-effectiveness analysis with Kenyan cost inputs, a budget-impact model against the relevant fund, local disease-burden data, equity considerations, implementation feasibility.

None of that is wasted if the procedure changes. A manufacturer that has the evidence assembled is positioned for whatever pathway is published; one waiting for the pathway before starting the evidence work is a year behind on the day it appears.

Kenya's HTA process is new and still taking shape. Working with it as it currently operates, and being plain about what is established and what is not, is the only honest position available.